Institutional shares held 53.3 Million
417K calls
314K puts
Total value of holdings $4.07B
$31.8M calls
$23.9M puts
Market Cap $3.92B
51,316,500 Shares Out.
Institutional ownership 103.84%
# of Institutions 351


Latest Institutional Activity in HAE

Top Purchases

Q2 2025
Central Pacific Bank Trust Division Shares Held: 7.62K ($582K)
Q1 2025
Wellington Management Group LLP Shares Held: 2.62M ($200M)
Q1 2025
River Road Asset Management, LLC Shares Held: 1.4M ($106M)
Q1 2025
Point72 Asset Management, L.P. Shares Held: 421K ($32.1M)
Q1 2025
Marshall Wace, LLP Shares Held: 649K ($49.5M)

Top Sells

Q2 2025
Confluence Investment Management LLC Shares Held: 39.9K ($3.04M)
Q1 2025
Capital Research Global Investors Shares Held: 1.58M ($120M)
Q1 2025
Thrivent Financial For Lutherans Shares Held: 529K ($40.4M)
Q1 2025
T. Rowe Price Investment Management, Inc. Shares Held: 2.2M ($168M)
Q1 2025
Voya Investment Management LLC Shares Held: 58.8K ($4.48M)

About HAE

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.


Insider Transactions at HAE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
183K Shares
From 16 Insiders
Grant, award, or other acquisition 183K shares
Sell / Disposition
107K Shares
From 10 Insiders
Payment of exercise price or tax liability 61.1K shares
Other acquisition or disposition 39.7K shares
Open market or private sale 6.53K shares

Track Institutional and Insider Activities on HAE

Follow HAEMONETICS CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HAE shares.

Notify only if

Insider Trading

Get notified when an Haemonetics Corp insider buys or sells HAE shares.

Notify only if

News

Receive news related to HAEMONETICS CORP

Track Activities on HAE